<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: <z:hpo ids='HP_0000001'>All</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA), an active metabolite of vitamin A, is widely used in the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> promyelocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, its high lipophilicity is thought to be responsible for the slow dissolution and low bioavailability following oral administration </plain></SENT>
<SENT sid="2" pm="."><plain>In order to obtain compounds with better solubility characteristics to improve the transportation and bioavailability of ATRA, derivatives of ATRA containing glutamic acid or its <z:chebi fb="8" ids="26714">sodium salt</z:chebi> were synthesised </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The ATRA derivatives synthesised - <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="0" ids="26539">retinoyl</z:chebi> <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (RAE) and <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="0" ids="26539">retinoyl</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (RAENa(2)) - were characterised in terms of melting point, optical rotation, mass spectrometry, NMR and partition coefficient </plain></SENT>
<SENT sid="4" pm="."><plain>A liposomal preparation formed from RAE was characterised by particle size and zeta potential </plain></SENT>
<SENT sid="5" pm="."><plain>The anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity of RAE and RAENa(2) was compared with that of ATRA in mice bearing S(180) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and their effects on the cell cycle were determined in human pro-myelocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 cells </plain></SENT>
<SENT sid="6" pm="."><plain>KEY FINDINGS: RAE and RAENa(2) were more active than ATRA against <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Flow cytometry indicated that RAE and RAENa(2) induced <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 cell cycle arrest, similar to ATRA </plain></SENT>
<SENT sid="8" pm="."><plain>DNA fragmentation studies suggested that <z:mpath ids='MPATH_3'>apoptosis</z:mpath> may be one of the mechanisms responsible for the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activities </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The two derivatives of ATRA, RAE and RAENa(2), exhibited improved aqueous solubility and were more effective in mice bearing S(180) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
</text></document>